solufilina

Oral Solution

ETAMIPHYLLINE CHLORHYDRATE (I.C.D.)

Due to the wide experience achieved by using SOLUFILINA and the excellent results obtained with its equally effective administration by all routes, with very good tolerability owing to the characteristics which distinguish this theophylline salt being chemically neutral, stable and soluble, have led to complete its presentation forms with another oral one, namel the oral solution, form, being suitable for paediatrics, thus complementing the already existing children and newborns suppositories.

Further to these qualities are their very specific therapeutical actions:
CARDIOTONIC, RESPIROTONIC, DIURETIC AND SPASMOLYTIC, thus turning in into an essential preparation in the cardiopulmonary pathology.

At the same time, and since it is a chemical substance with perfectly well defined formula and not of an association, it shows a steadiness of action, and is applicable by all routes with equal therapeutical effectiveness.

COMPOSITION:	**15 ml**	**4,5 ml**	**1,5 ml**
Etamiphylline chlorhydrate (I.C.D.)	250 mg	75 mg	25 mg
Sodium saccharine	50 mg	15 mg	5 mg
Excipient s.q.			

INDICATIONS

Treatment of all forms of asthma. Bronchitis. Dyspnea conditions. Cardiorespiratory insufficiency. Myocardial infarction. Cardiopathy in adult and children. Vesicular, intestinal and urethral spasms.

DOSAGE: Unless other medical prescription, the recommended dosage are:

ADULTS: From 6 to 12 daily dose measures of 7,5 ml.
CHILDREN: From 3 to 6 daily dose measures of 4,5 ml.
NEWBORNS: From 2 to 6 daily dose measures of 1,5 ml.

CONTRAINDICATIONS AND INCOMPATIBILITIES: Not know.

SIDE EFFECTS: The tolerability of this preparation is optimal.

INTOXICATION AND TREATMENT

As the terapeutical dose is far from the LD50, no intoxication may arise unless intentionally or by accidental massive ingestion. The treatment should be gastric lavage and administration of phenobarbital sedative compounds.

HOW SUPPLIED: Bottle containing 250 ml oral solution.

Under medical prescription.

DRUGS MUST BE KEPT OUT OF THE REACH OF CHILDREN

Manufactured by **LABORATORIOS B.O.I., S.A.**
Technical Director: Dr. A. M.ª LLUCH
PAPIOL, Barcelona (Spain)

32.90.007-A